Glaukos delivered fourth-quarter reported revenue of $143.1 million, up 36% year-over-year, with adjusted gross profit rising 40.3% to $121.8 million and gross margin expanding to 85.1%. GAAP loss per share widened to $2.32 while adjusted loss narrowed to $0.28, and cash plus short-term investments ended at $282.6 million.

The company raised its 2026 net sales forecast to $600–620 million, compared with the $610.6 million consensus, and projects a loss per share of $0.33, a 60.9% improvement year over year. Management highlighted expectations for sustained momentum from iDose TR and the commercial launch of Epioxa driving durable double-digit revenue growth.

Strong U.S. glaucoma growth stemmed from rapid iDose TR adoption under expanded labeling, while global MIGS investments support international market share gains. The FDA’s approval of Epioxa marks the first topical cross-linking therapy for keratoconus, with site-of-care expansion underway and J-code reimbursement expected in July 2026, alongside other late-stage pipeline programs.